PMV Pharmaceuticals Inc expected to post a loss of 38 cents a share - Earnings Preview

Pmv Pharmaceuticals

04/08/2025 14:47

PMV Pharmaceuticals Inc PMVP.OQ PMVP.O is expected to  show no change in quarterly revenue when it reports  results on August 6 (estimated) for the period ending June 30 2025

​LSEG's mean analyst estimate for PMV Pharmaceuticals Inc is for a loss of 38 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for PMV Pharmaceuticals Inc is $6.00, about 76.7% above its last closing price of $1.40

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.38
-0.37
-0.34
Beat
9.2
Dec. 31 2025
-0.39
-0.38
-0.45
Missed
-18.2
Sep. 30 2024
-0.36
-0.35
-0.37
Missed
-5.4​
Jun. 30 2024
-0.35
-0.35
-0.02
Beat
94.3
​​Mar. 31 2024
-0.35
-0.36
-0.30
Beat
16.8
Dec. 31 2023
-0.38
-0.39
-0.31
Beat
19.7​
Sep. 30 2023
-0.45
-0.45
-0.34
Beat
23.8
Jun. 30 2023
-0.46
-0.47
-0.38
Beat
20

This summary was machine generated August 4 at 13:47 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)